Advertisement

Picture EBD Group BioPharm America 2019 Boston September 650x65px
Organisation › Details

4SC (Group)

4SC AG is a clinical-stage biopharmaceutical company developing small-molecule drugs that can target key indications in cancer with high unmet medical needs. 4SC’s pipeline is protected by a comprehensive portfolio of patents and currently comprises two drug candidates in clinical development: resminostat and domatinostat. 4SC aims to generate future growth and enhance its enterprise value by entering into partnerships with pharmaceutical and biotech companies and/or the eventual marketing and sales of approved drugs in select territories by 4SC itself. 4SC is headquartered in Planegg-Martinsried near Munich, Germany. The Company had 47 employees as of 31 March 2019 and is listed on the Prime Standard of the Frankfurt Stock Exchange (FSE Prime Standard: VSC; ISIN: DE000A14KL72). *

 

Please contact us with your proposals. Thank you!
Period Start 1997-01-01 established
Period End  renamed
Products Industry BIOTECH
  Industry 2 resminostat (4SC-201)
Persons Person Loveridge, Jason (4SC 201609– CEO)
  Person 2 Doppler, Clemens (3i Germany 2007 Director Healthcare Team)
     
Region Region Martinsried
  Country Germany
  Street 22 Fraunhoferstr.
  City 82152 Martinsried
  Tel +49-89-700763-0
    Address record changed: 2018-07-24
     
Basic data Employees B: 11 to 50 (2019-03-31)
  Currency EUR
  Annual sales 4,197,000 (revenue, consolidated (2017) 2017-12-31)
  Profit -10,960,000 (2017-12-31)
  Cash 41,548,000 (2017-12-31)
     
    * Document for �About Section�: 4SC AG. (6/28/19). "Press Release: 4SC AG Secures EUR 11 Million from Capital Increase [Ad hoc, not for US, AU, CA, JP, ZA, et al.]". Planegg-Martinsried.
     
   
Record changed: 2019-07-03

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 650x112px

More documents for 4SC (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BioPharm America 2019 Boston September 650x65px




» top